The purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved clinical status and quality of life. Funding Source - FDA OOPD (Food and Drug Administration - Office of Orphan Products Development)
Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation, Microcystic Lymphatic Malformation, Mucocutaneous Lymphangiomatosis and Thrombocytopenia, Capillary Lymphatic Arterial Venous Malformations, PTEN Overgrowth Syndrome With Vascular Anomaly, Lymphangiectasia Syndromes
Patients with vascular anomalies (VA) have a spectrum of diseases that can be broadly classified into vascular tumors and malformations. Complicated vascular anomalies can cause disfigurement, chronic pain, and organ dysfunction with significant morbidity and mortality. Despite the severity of potential complications, we lack uniform guidelines for the treatment and response to treatment of children and young adults with these diseases. There are pre-clinical and clinical data supporting the essential regulatory function of the PI3K/Akt/mTOR pathway in vascular growth and organization, and suggest a therapeutic target for patients with complicated vascular anomalies. The overall goal of this trial is to objectively determine the effectiveness and safety of the mTOR inhibitor Rapamycin* in the treatment of children and young adults diagnosed with complicated vascular anomalies. We propose a Phase 2 trial with the diagnostic, therapeutic and response criteria experimentally determined in this study used as a framework for future Phase 3 clinical trials.
Inclusion will be strictly limited to children and young adults with vascular anomalies with complications that require systemic therapy for control.
Diagnosis: All patients must have one of the following vascular anomalies as determined by clinical, radiographic and histologic criteria (when possible):
Kaposiform Hemangioendotheliomas with Kasabach-Merritt Phenomenon
Kaposiform Hemangioendotheliomas without Kasabach-Merritt Phenomenon
Tufted Angioma with Kasabach-Merritt Phenomenon
Tufted Angioma without Kasabach-Merritt Phenomenon
Capillary Lymphatico-Venous Malformation (CLVM)
Venous Lymphatic Malformation (VLM)
Microcystic Lymphatic Malformation (MLM)
Multifocal Lymphangiomatosis and Thrombocytopenia (MLT)/Cutaneovisceral Angiomatosis and Thrombocytopenia (CAT)
Capillary Lymphatic Arterial Venous Malformations (CLAVM)
PTEN Overgrowth syndrome with vascular anomaly
If archived tissue is available, histological diagnosis will be confirmed by the pathology lab at the enrolling site.
Complications: Patients must have vascular anomalies that have potential to cause significant morbidity. In addition to the above diagnosis, one or more of the following criteria needs to be met:
Recurrent cellulitis (>3 episodes/year)
Visceral and/or bone involvement
Age: Patients must be 0 - 31 years of age at the time of study entry. Enrollment includes patients of both genders and all ethnic groups.
Organ function requirements:
Adequate liver function defined as:
Total bilirubin (sum of conjugated and unconjugated) ≤1.5 x ULN for age, and
SGPT (ALT) <5 x ULN for age, and
Serum albumin > or = 2 g/dL.
Fasting LDL and cholesterol:
Fasting LDL cholesterol of <160 mg/dL
Patients taking a cholesterol lowering agent must be on a single medication and on a stable dose for at least 4 weeks
Adequate Bone Marrow Function defined as:
Peripheral absolute neutrophil count (ANC) > or = 1000/microL
Hemoglobin > or = 8.0 gm/dL (may receive RBC transfusions)
Platelet count > or = 50,000/microL (transfusion independent defined as not receiving a platelet transfusion within a 7 day period prior to enrollment)
Note: There is NO platelet requirement for patients with Kasabach-Merritt Phenomenon
Adequate Renal Function Defined as:
• A serum creatinine based on age as follows:
≤ 5 years of age maximum serum creatinine (mg/dL) of 0.8
6 < age ≤ 10 years of age maximum serum creatinine (mg/dL) of 1.0
11 < age ≤ 15 years of age maximum serum creatinine (mg/dL) of 1.2
> 15 years of age maximum serum creatinine (mg/dL) of 1.5
AND cystatin C equal to or less than the upper limit of normal for the patient. If cystatin C does not initially meet this criterion, it may be repeated or a more sensitive screening by nuclear GFR must be ≥ 70 ml/min.
• Urine protein to creatinine ratio (UPC) < 0.3 g/l
Performance Status: Karnofsky > or = 50 (>10 years of age) and Lansky > or = 50 for patients < or = 10 years of age
Prior therapy requirements:
Patients who have undergone surgical resection or interventional radiology procedures for disease control are eligible if they meet all inclusion criteria after surgery/procedure
Surgery: At least 2 weeks since undergoing any major surgery
Steroids: Patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary. Other patients, such as vascular tumor patients, need to be on a weaning dose of steroids (steroid use defined as intravenous or oral steroids required for more than one day).
Myelosuppressive chemotherapy: Must not have received within 4 weeks of entry onto this study.
Hematopoietic GFs: At least 7 days since the completion of therapy with a GF that supports platelet, red or white cell number or function.
Biologic (anti-neoplastic agent): At least 14 days since the completion of therapy with a biologic agent. For agents that have known AEs occurring beyond 14 days after administration, this period must be extended beyond the time during which AEs are known to occur. These patients must be discussed with the Study Chair on a case-by-case basis.
Patients diagnosed with Kaposiform Hemangioendotheliomas or Tufted Angiomas will not require a washout period prior to enrollment, but will be required to discontinue the use of prohibited concomitant medications upon enrollment in the study following the guidelines of the protocol.
Investigational Drugs: Patients must not have received any non-FDA approved drug within 4 weeks.
XRT: > or = 6 months from involved field radiation to vascular tumor.
CYP3A4 inhibitors: Patients may not be currently receiving strong inhibitors of CYP3A4, and may not have received these medications within 1 week of entry. (See Appendix II). These include:
Macrolide Antibiotics: clarithromycin, telithromycin, erythromycin, troleandomycin.
Gastrointestinal prokinetic agents: cisapride, metoclopramide.
Antifungals: itraconazole, ketoconazole, fluconazole (doses > 200 mg/day), voriconazole, clotrimazole
Calcium channel blockers: verapamil, diltiazem, nicardipine
Other drugs: rifampin, bromocriptine, cimetidine (Tagamet®), danazol, cyclosporine oral solution, lansoprazole (Prevacid®).
CYP3A4 inducers: Patients must also avoid strong inducers of CYP3A4, and may not have received these medications within 1 week of entry. These include:
Anticonvulsants: carbamazepine, phenobarbital, phenytoin
Antibiotics: rifabutin, rifapentine.
Herbal preparations: St. John's Wort (Hypericum perforatum, hypericine).
Enzyme inducing anticonvulsants: Patients may not be taking enzyme-inducing anticonvulsants, and may not have received these medications within 1 week of entry, as these patients may experience different drug disposition. These medications include:
Dental braces or prosthesis only if it interferes with radiologic analysis of vascular anomaly.
Concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration).
Chronic treatment with systemic steroids or another immunosuppressive agent. Patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary. Patients with the diagnosis of a vascular tumor (KHE, TA) can be on a weaning dose of steroids.
Patients who require medications that inhibit/induce CYP3A4 enzyme activity to control concurrent medical conditions.
Known history of HIV seropositivity or known immunodeficiency. Testing is not required unless a condition is suspected.
Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of sirolimus (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). A gastric tube or nasogastric tube is allowed.
Women who are pregnant or breast feeding.
Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during the period they are receiving the study drug and for 3 months thereafter. Abstinence is an acceptable method of birth control. Women of childbearing potential will be given a pregnancy test within 7 days prior to administration of sirolimus and must have a negative urine or serum pregnancy test.
Patients who have received prior treatment with an mTOR inhibitor.
Patients unwilling or unable to comply with the protocol, or who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
Patients who currently have an uncontrolled infection, defined as receiving intravenous antibiotics.
February 5, 2015
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: